CRISPR/Cas9 gene editing technology can directly edit PD-1/PD-L1 or indirectly regulate antigen presentation and upstream and downstream signaling pathways to improve a variety of immune cells and the tumor microenvironment, and combat tumor immunosuppression. The gene discussed is PDCD1; the disease is neoplasm.